Q&A with hVIVO’s Mo Khan: “£80 million is the highest starting order book in the history of the company.
Vox Markets talks to(HVO ) chief executive Mo Khan on a year that saw the human challenge trial specialist beat previously upgraded Ebitda guidance and start 2024 with the company’s highest ever starting order book, laying a solid foundation for its next phase of growth.
0:29 Mo Khan talks through the highlights of hVIVO’s expectation-beating FY23 trading update.
1:28 How operational gearing is flowing through into a rapidly increasing Ebitda margin.
2:22 What’s behind the increase in the order book to a record £80m, including an expanded range of human challenge models and increasing contract sizes.
4:07 The outlook for 2024, including 90% of revenue already contracted and the opening of the Canary Wharf facility that expands the group’s revenue capacity to over £90m of annual revenue.
5:31 How the new facility will further support margin expansion.
6:03 Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions.
7:26 The introduction of a dividend policy and the cash generative qualities of the group that underpins it.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.